EP1117691A1 - Production d'anticorps specifiques d'antigenes tumoraux humains - Google Patents

Production d'anticorps specifiques d'antigenes tumoraux humains

Info

Publication number
EP1117691A1
EP1117691A1 EP99949891A EP99949891A EP1117691A1 EP 1117691 A1 EP1117691 A1 EP 1117691A1 EP 99949891 A EP99949891 A EP 99949891A EP 99949891 A EP99949891 A EP 99949891A EP 1117691 A1 EP1117691 A1 EP 1117691A1
Authority
EP
European Patent Office
Prior art keywords
antigen
cells
terminus
chimera
immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99949891A
Other languages
German (de)
English (en)
Inventor
Ugur Sahin
Ozlem Tureci
Michael Pfreundschuh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Original Assignee
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research Ltd
Publication of EP1117691A1 publication Critical patent/EP1117691A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Definitions

  • the claimed invention relates generally to the detection and isolation of B lymphocyte cells that secrete tumor antigen specific antibodies, as well as to the purification of such antibodies and the genes that encode these antibodies.
  • the invention further relates to compositions comprising tumor antigens fused to immunoglobulin Fc domains as well as methods of using the compositions to detect tumor antigen specific antibodies and the B cells which secrete these antibodies.
  • neoantigens The genes which are expressed in neoplastic or tumor cells, but not in normal cells, or which are expressed in neoplastic cells at levels substantially above those found in normal cells, have been termed tumor specific genes and their gene products, "neoantigens.” Such neoantigens may serve as markers for tumor phenotype (Roitt, et al., in Immunology (2nd ed), pp 18.1-18.18, Gower Medical Publishing, New York, NY (1989)).
  • MAGE, BAGE, GAGE, PRAME and NY-ESO-1 cancer/testis-specific antigen
  • melanocyte differentiation antigens tyrosinase, Melan- A/MART, gplOO, TRP-1 and TRP-2
  • mutated or aberrantly expressed antigens MUM- 1 , CDK4, beta-catenin, gp 100-in4, p 15 and N-acetylglucosaminyltransferase V.
  • MUM- 1 , CDK4, beta-catenin, gp 100-in4, p 15 and N-acetylglucosaminyltransferase V See Kirkin, et al., APMIS 106: 665-679 (1998).
  • These antigen molecules may serve as reagents which can be used to generate diagnostic and/or therapeutic agents.
  • the present invention provides methods of generating recombinant human antibodies directed against cancer associated tumor antigens comprising the steps of: a) isolating peripheral blood lymphocytes from tumor bearing patients; b) detecting or identifying B-cell clones producing antibodies from these lymphocytes; c) isolating cDNA encoding immunoglobulins from such B-cell clones; d) expressing the immunoglobulin encoded by the cDNA of step (c); and e) isolating the immunoglobulin as a functional antibody.
  • the present invention also includes methods of detecting and isolating human B cell clones which produce tumor antigen specific antibodies.
  • antibody as used herein, unless indicated otherwise, is used broadly to refer to both antibody molecules and a variety of antibody derived molecules.
  • Such antibody derived molecules comprise at least one variable region (either a heavy chain of light chain variable region) and include molecules such as Fab fragments, Fab' fragments, F(ab')2 fragments, Fd fragments, Fabc fragments, Sc antibodies (single chain antibodies), diabodies, individual antibody light chains, individual antibody heavy chains, chimeric fusions between antibody chains and other molecules, and the like.
  • Antibodies described herein may contain alterations of the amino acid sequence compared to a naturally occurring antibody.
  • the framework regions of some of the antibodies of the invention do not necessarily consist of the precise amino acid sequence of the framework region of a natural occurring human antibody variable region, but contain various substitutions that improve the binding properties of the antibody to its cognate antigen or change the binding of the antibody to effector molecules such as complement or the Fc receptor.
  • a minimal number of substitutions are made to the framework region in order to ensure minimal immunogenicity of the antibody in humans.
  • any non-human framework regions used may be altered with a minimal number of substitutions to the framework region in order to avoid large-scale introductions of non-human framework residues.
  • conventional molecular biology methods refers to techniques for manipulating polynucleotides that are well known to the person of ordinary skill in the art of molecular biology. Examples of such well known techniques can be found in Molecular Cloning: A Laboratory Manual 2nd Edition, Sambrook et al, Cold Spring Harbor, N.Y. (1989). Examples of conventional molecular biology techniques include, but are not limited to, in vitro Hgation, restriction endonuclease digestion, PCR, cellular transformation, hybridization, electrophoresis, DNA sequencing, cell culture, and the like.
  • variable region as used herein in reference to immunoglobulin molecules has the ordinary meaning given to the term by the person of ordinary skill in the art of immunology. Both antibody heavy chains and antibody light chains may be divided into a "variable region” and a "constant region". The point of division between a variable region and a contrast region may readily be determined by the person of ordinary skill in the art by reference to standard texts describing antibody structure, e.g., Kabat et al "Sequences of Proteins of Immunological Interest: 5th Edition" U.S. Department of Health and Human Services, U.S. Government Printing Office (1991).
  • Fusion proteins may be prepared comprising a fusion between any antigen, preferably a tumor antigen, and an IgG constant region, preferably a murine Fc region, using conventional molecular biology methods.
  • the pSecTagA expression vector may be used for mammalian expression of the fusion proteins.
  • a vector containing the cDNA for murine IgG heavy chain constant region is generated.
  • a cDNA for a murine IgGl heavy chain constant region fragment IgGl-Fc may be cloned from any murine hybridoma cell clone which produces a IgGl monoclonal antibody by PCR amplification of the appropriate fragment.
  • the IgGl-Fc fragment may then be cloned into any appropriate expression vector which allows replication and expression of the resulting fusion protein.
  • This plasmid may then be used as a basis for Hgation of the tumor antigen cDNA fragment of interest upstream of the IgG-Fc cDNA to allow the expression of fusion proteins.
  • resulting fusion proteins contain an antigen part, an IgG-Fc part, a cmyc-tail and 6xhis (allowing simple purification and detection).
  • the generated constructs may be transferred into other expression vectors.
  • the Pichia vector pPicZalpha Invitrogen
  • the Baculovirus expression vector pMelBac Invitrogen
  • the identity of the tumor antigen entity to be fused to the IgG Fc region may be variable depending on the specific antigen, the degree of characterization of the antigen, the localization of immunologically relevant epitopes, etc.
  • full length antigen cDNAs may be used to produce a fusion protein comprising the full length tumor antigen fused in frame to the Fc portion.
  • cDNA fragments encoding immunologically relevant portions of the tumor antigen may be used to produce fusion proteins, e.g., particular B cell epitopes.
  • Antigen specific B cells may be isolated from convenient samples, such as peripheral blood lymphocytes from a cancer patient, by techniques known and available in the art.
  • fusion proteins of the invention may be used to detect and isolate B cells which express immunoglobulin which specifically binds to the tumor antigen portion of the fusion protein by affinity chromatography, fluorescent activated cell sorting (FACS) and other commonly used techniques such as Zn-chelating sepharose or protein- A sepharose (see Harlow et al, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988).
  • tumor draining lymph nodes obtained from a cancer patient may be cut into fine pieces and meshed through a wire gauze using a rubber policeman.
  • Pure B cells may be isolated using CD 19 coated immunomagnetic beads.
  • Antigen specific B cells may be isolated using the appropriate fusion protein by affinity chromatography or fluorescent activated cell sorting.
  • the resulting tumor antigen specific B cells may then be immortalized using known techniques such as immortalization by EBV. Any effective lymphotropic virus or other transforming agent able to transform the B-cells to grow in continuous culture and still produce monoclonal antibodies specific for tumor associated antigens can be used.
  • the subject invention provides for polynucleotides encoding human tumor specific antibodies.
  • the polynucleo tides may have a wide variety of sequences because of the degeneracy of the genetic code.
  • a person of ordinary skill in the art may readily change a given polynucleotide sequence encoding a tumor specific antibody into a different polynucleotide encoding the same human tumor specific antibody.
  • the polynucleotide sequence encoding the antibody may be varied to take into account factors affecting expression such as codon frequency, RNA secondary structure, and the like.
  • the antibodies of the subject invention may be produced by a variety of methods useful for the production of polypeptides, e.g., in vitro synthesis, recombinant DNA production, and the like.
  • humanized antibodies are produced by recombinant DNA technology.
  • the antigen specific antibodies of the invention may be produced using recombinant immunoglobulin expression technology.
  • the recombinant production of immunoglobulin molecules, including humanized antibodies is described in U.S. Pat. No. 4,816,397 (Boss et al), U.S. Pat. No. 4,816,567 (Cabilly et al), U.K. patent GB 2,188,638 (Winter et al), and U.K. patent GB 2,209,757.
  • Techniques for the recombinant expression of immunoglobulins, including humanized immunoglobulins can also be found, among in Goeddel et al, Gene Expression Technology Methods in Enzymology Vol. 185 Academic Press (1991), and Borreback, Antibody Engineering, W. H. Freeman (1992). Additional information concerning the generation, design and expression of recombinant antibodies can be found in Mayforth, Designing Antibodies, Academic Press, San Diego (1993).
  • the recombinant antibodies of the invention may be produced by the following process: a) constructing, by conventional molecular biology methods, an expression vector comprising a nucleotide sequence that encodes an antibody heavy chain in which the CDRs and a minimal portion of the variable region framework that are required to retain donor antibody binding specificity are derived from the human immunoglobulin, and the remainder of the antibody is derived from another human immunoglobulin, thereby producing a vector for the expression of a humanized antibody heavy chain; b) constructing, by conventional molecular biology methods, an expression vector comprising a nucleotide sequence that encodes an antibody light chain in which the CDRs and a minimal portion of the variable region framework that are required to retain donor antibody binding specificity are derived from the human immunoglobulin, and the remainder of the antibody is derived from another human immunoglobulin, thereby producing a vector for the expression of humanized antibody light chain; c) transferring the expression vectors to a host cell by conventional molecular biology methods to produce
  • Host cells may be cotransfected with two expression vectors of the invention, the first vector encoding a heavy chain derived polypeptide and the second encoding a light chain derived polypeptide.
  • the two vectors may contain different selectable markers but, with the exception of the heavy and light chain coding sequences, are preferably identical. This procedure provides for equal expression of heavy and light chain polypeptides.
  • a single vector may be used which encodes both heavy and light chain polypeptides.
  • the coding sequences for the heavy and light chains may comprise cDNA or genomic DNA or both.
  • the host cell used to express the recombinant antibody of the invention may be a bacterial cell such as Escherichia coli, or antigen binding fragments may be expressed in available phage display systems (see Winter et al. (1994) Ann. Rev. Immunol., 12:433- 455 and Little et al. (1995) J. Biotechnol., 41(2-3):187-195).
  • a eukaryotic cell or most preferably a mammalian cell, such as a Chinese hamster ovary cell may be used.
  • the choice of expression vector is dependent upon the choice of host cell, and may be selected by a person skilled in the art so as to have the desired expression and regulatory characteristics in the selected host cell.
  • the general methods for construction of the vector of the invention, transfection of cells to produce the host cell of the invention, culture of cells to produce the antibody of the invention are all conventional molecular biology methods.
  • the recombinant antibodies of the invention may be purified by standard procedures of the art, including cross-flow filtration, ammonium sulphate precipitation, affinity column chromatography, gel electrophoresis and the like.
  • the antibodies of the present invention may be used in conjunction with, or attached to other antibodies (or parts thereof) such as human or humanized monoclonal antibodies. These other antibodies may be reactive with other markers (epitopes) characteristic for the disease against which the antibodies of the invention are directed or may have different specificities chosen, for example, to recruit molecules or cells of the human immune system to the diseased cells.
  • the antibodies of the invention (or parts thereof) may be administered with such antibodies (or parts thereof) as separately administered compositions or as a single composition with the two agents linked by conventional chemical or by molecular biological methods.
  • the diagnostic and therapeutic value of the antibodies of the invention may be augmented by labeling the humanized antibodies with labels that produce a detectable signal (either in vitro or in vivo) or with a label having a therapeutic property.
  • Some labels e.g. radionuclides may produce a detectable signal and have a therapeutic property. Examples of radionuclide labels include 125 I and 131 I.
  • Examples of other detectable labels include a fluorescent chromophore such as fluorescein, phycobiliprotein ortetraethyl rhodamine for fluorescence microscopy, an enzyme which produces a fluorescent or colored product for detection by fluorescence, absorbance, visible color or agglutination, which produces an electron dense product for demonstration by electron microscopy; or an electron dense molecule such as ferritin, peroxidase or gold beads for direct or indirect electron microscopic visualization.
  • Labels having therapeutic properties include drugs for the treatment of cancer, such as methotrexate and the like.
  • the subject invention also provides for a variety of methods for treating and/or detecting cancer cells. These methods involve the administration to a cancer patient of tumor specific antibodies, either labeled or unlabeled.
  • One method of detecting cancer cells in a human involves the step of administering a labeled tumor specific antibody (labeled with a detectable label) to a human and subsequently detecting bound labeled antibody by the presence of the label.
  • the tumor specific antibodies may be linked or conjugated to a therapeutic molecule such as ricin or other toxins.
  • the recombinant antibodies of this invention may also be used for the selection and/or isolation of human monoclonal antibodies, and the design and synthesis of peptide or non-peptide compounds (mimetics) which would be useful for the same diagnostic and therapeutic applications as the antibodies (e.g. Saragovi et al., (1991) Science 253:792-795).
  • the antibodies are typically administered in a composition comprising a pharmaceutical carrier.
  • a pharmaceutical carrier can be any compatible, non-toxic substance suitable for delivery of the monoclonal antibodies to the patient. Sterile water, alcohol, fats, waxes, and inert solids may be included in the carrier. Pharmaceutically accepted buffering agents or dispersing agents may also be incorporated into the pharmaceutical composition.
  • the antibody compositions of the invention may be administered to a patient in a variety of ways. Preferably, the compositions may be administered parenterally, i.e., subcutaneously, intramuscularly or intravenously.
  • compositions for parenteral administration which comprise a solution of the human antibody or a cocktail thereof dissolved in an acceptable carrier, preferably an aqueous carrier.
  • an acceptable carrier preferably an aqueous carrier.
  • aqueous carriers can be used, e.g., water, buffered water, 0.4% saline, 0.3% glycine and the like. These solutions are sterile and generally free of particulate matter.
  • These compositions may be sterilized by conventional, well known sterilization techniques.
  • the compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate, etc.
  • the concentration of antibody in these formulations can vary widely, e.g., from less than about 0.5%, usually at or at least about 1% to as much as 15 or 20% by weight and will be selected primarily based on fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.
  • Example 1 Preparation of Fc fusion vector Plasmids were prepared for the expression of a secreted chimeric fusion protein consisting of an N-terminal SEREX antigen and C-terminal murine IgG heavy chain constant region.
  • the pSecTagA plasmid (Invitrogen) was used in a two step cloning technique for the generation of new expression vectors.
  • the pSecTagA-mlgGl-Fc vector was generated by ligation of an amplified murine IgGl constant region cDNA fragment into the pSecTagA plasmid.
  • mRNA was extracted from the murine hybridoma cell clone producing an IgGl monoclonal antibody using standard techniques.
  • First strand cDNA was synthesized using dT(18) primed mRNA and reverse transcriptase (Superscript, Gibco) with supplied buffers and conditions. Synthesis was performed at 42 °C for 45 min. This first strand cDNA was used to amplify a IgGl constant region cDNA fragment using polymerase chain reaction. Amplification was performed with oligonucleotides containing an Xhol restriction site.
  • oligonucleotides were used: mlgGl-S CTC GAG gtg gac aag aaa att gtg ccc agg; and mlgGl-AS CTC GAG aga gtg gga gag get ctt etc agt atg.
  • Amplification was performed for 30 cycles with annealing at 64°C for 1 min, extension at 72 °C for 2 min, denaturation 94 °C for 1 min followed by a final extension at 72 °C for 8 min.
  • the 699 bp amplified fragment was cloned into a TA- Overhang vector (TA cloning kit, Invitrogen). The integrity of the sequence was verified by sequencing with vector specific oligonucleotides using standard techniques. After sequence verification, the murine IgGl cDNA fragment was cut from the TA vector using Xhol digestion and was ligated into Xhol digested, dephosphorylated pSecTagA vector.
  • cDNAs for the various tumor antigens were amplified using specific oligonucleotides from human first-strand cDNA derived from testis (for SCPl, NYESOl, MAGE3), melanoma (tyrosinase), breast cancer (cErbB2) or seminoma (HERV-K10 gag). Amplification of cDNAs were performed with oligonucleotides containing restriction enzyme digestion sites.
  • Amplified cDNAs were cloned into TA-Overhang vectors (TA cloning kit Invitrogen). The integrity of sequences were verified by sequencing with vector specific oligonucleotides using standard techniques. After sequence verification the cDNAs were cut out from the TA- vectors and were ligated in pSecTagA-mlgG-Fc vector.
  • SCPl-cDNA fragments containing EcoRl overhangs Amplification with specific oligonucleotides SCPl -SI and SCPl -AS 1 (both containing EcoRl sites) was used to obtain the SCPl coding sequence (see U.S. Patent Application 08/892,702). Amplification was performed using testis cDNA for 35 cycles with annealing at 64 °C for 1 min, extension at 72 °C for 2 min, denaturation 94 °C for 1 min followed by a final extension at 72 °C for 8 min.
  • oligonucleotides were used: SCPl -SI a gga att etc caa gcc aga gag aaa gaa gta cat; and SCPl -AS 1 ag gaa ttc tga gtc tct ttc ttc aat gat ctt ate ata.
  • oligonucleotides were used: NY-ESOl-S-EcoRl gaa ttc cca tgc agg ccg aag aag gcc; and NY-ESO 1 -AS gaa ttc ctg cag ttg gcg gtg gtc.
  • the insert was cut with EcoRl and ligated into pSecTagB-mlgGFc precut with EcoRl resulting in pSecTagA-NY-Esol-mlgGFc.
  • Tyrosinase cDNA was amplified with specific oligonucleotides Tyrosinase-S, (containing a BamHl site) and Tyrosinase- AS (containing an EcoRl site) (the sequence of the tyrosinase cDNA is available in GenBank). Amplification was performed using melanoma derived first strand cDNA for 35 cycles with annealing at 64 °C for 1 min, extension at 72 °C for 2 min, denaturation 94 °C for 1 min followed by a final extension at 72 °C for 8 min. The amplified fragment was cloned into TA-Overhang vector (TA cloning kit, Invitrogen).
  • TA-Overhang vector TA cloning kit, Invitrogen
  • Tyrosinase-S (BamHl) ag gat cca cat ttc cct aga gcc tg gtc tec tct; and Tyrosinase- AS (EcoRl) a gaa ttc tag ata get ata gtc ata gcc cag ate.
  • cErbB2(HER2/neu) cDNA was amplified with specific oligonucleotides cErbB2-S, (containing Sfil and Sail sites) and cErbB2-AS (containing a Muni site) (the sequence of cErbB2 is available in GenBank). Amplification was performed for 35 cycles with annealing at 64 °C for 1 min, extension at 72 °C for 3 min, denaturation 94 °C for 1 min followed by a final extension at 72 °C for 8 min.
  • oligonucleotides were used: cErbB2-S ag gcc cag ccg gcc atg teg aca age ace caa gtg tgc ace ggc aca gac; and cErbB2-AS caa ttg gat gga cgt cag agg get ggc tct atg.
  • the amplified fragment was cloned into a TA-Overhang vector (TA cloning kit
  • the insert was cut with Sfil and Muni and ligated into pSecTagA-mlgGFc precut with Sfil/EcoR7 resulting in pSecTagA-c ⁇ rbB2-mIgGFc.
  • Example 6 Preparation of MAGE -3 fusions Cloning of MAGE- 3 cDNA fragment containing Kpnl sites: Amplification was done with specific oligonucleotides MAGE3-S and MAGE3-AS (both containing Kpnl sites) (see WO92/20356). Amplification was performed using MAGE3-plasmid provided from Pierre van der Bruggen (LICR, Brussel) for 20 cycles with annealing at 60 °C for 1 min, extension at 72 °C for 2 min, denaturation 94 °C for 1 min followed by a final extension at 72 °C for 8 min.
  • ILR Pierre van der Bruggen
  • oligonucleotides were used: MAGE3-Kpnl-S-acc aga gtc atg gta cct ctt gag cag agg agt; and MAGE3-Kpnl-AS ggt ace etc tct tec ccc tct etc aaa ace cac tc.
  • the amplified fragment was cloned into a TA-Overhang vector (TA cloning kit Invitrogen). After determining identity the insert was cut with Kpnl and ligated into pSecTagA-mlgGFc precut with Kpnl resulting in pSecTagA- MAGE3-mIgGFc.
  • TA-Overhang vector TA cloning kit Invitrogen
  • fusion proteins in CHO cells Plasmids generated in the above Examples were transfected into CHO cells using Superfect (Qiagen) transfection reagent. Selection of transfected cells was performed with culture in Zeocin. Fusion protein secretion from CHO cells was measured by an mlgG ELISA. To enable high concentration of secretion, cells were subcloned in microtiter plates and tested for high level producers by ELISA. Using a high density culture system (Technomouse from Technomara) concentrations of secreted fusion proteins ranging from l ⁇ g/ml to 15 ⁇ g/ml were achieved. The supernatants of transfected cells were collected and stored at -80 °C until usage.
  • Example 8 Detection of antigen specific B lymphocytes in tumor specimens.
  • B cells and plasma cells For the detection of antigen specific in situ B cells and plasma cells cryosections of human tumors were prepared. These sections were stained with the fusion proteins in 1 ⁇ g/ml concentration (a prior enrichment or purification of the fusion protein (SEREX- Ag-Dimers)) is not necessary. In situ bound SEREX-Ag dimers were visualized with secondary IgG specific antibodies linked to enyzmes or biotin using standard systems. Staining of B-cells and plasma cells were observed in breast cancer tissues for SCPl-Fc and NY-Esol-Fc. The nature of stained cells was analyzed by staining of parallel tissue sections with CD20 or anti-human-IgG antibodies. 60 tumor samples were tested.
  • tumors Nearly one third of tested tumors express significant amounts of SCPl- Ag binding B lymphocytes (the number may be underestimated since several tumor specimens were very small). Some tumors have a high density of antigen specific B-lymphocytes. In the majority of cases there are focal aggregates of antigen specific B lymphocytes. Most antigen specific cells are located in fibrous areas. In several cases single positive cells are scattered through the tumor sample.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Cette invention concerne des méthodes permettant de produire des anticorps humains recombinants dirigées contre des antigènes associés aux tumeurs cancéreuses. Ces méthodes consistent à isoler des lymphocytes périphériques du sang dirigés contre chez des patients atteints de tumeurs, à détecter ou à identifier des clones de lymphocytes B produisant des anticorps à partir de ces lymphocytes, à isoler, à partir de ces clones de lymphocytes B, des immunoglobulines codant pour l'ADNc, à exprimer l'ADNc codé par l'immunoglobuline et à isoler cette immunoglobuline en tant qu'anticorps fonctionnel.
EP99949891A 1998-10-05 1999-09-28 Production d'anticorps specifiques d'antigenes tumoraux humains Withdrawn EP1117691A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10314098P 1998-10-05 1998-10-05
US103140P 1998-10-05
PCT/US1999/022314 WO2000020460A1 (fr) 1998-10-05 1999-09-28 Production d'anticorps specifiques d'antigenes tumoraux humains

Publications (1)

Publication Number Publication Date
EP1117691A1 true EP1117691A1 (fr) 2001-07-25

Family

ID=22293605

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99949891A Withdrawn EP1117691A1 (fr) 1998-10-05 1999-09-28 Production d'anticorps specifiques d'antigenes tumoraux humains

Country Status (3)

Country Link
EP (1) EP1117691A1 (fr)
AU (1) AU6266899A (fr)
WO (1) WO2000020460A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2378949B (en) * 2001-08-16 2005-09-07 Morten Steen Hanefeld Dziegiel Recombinant anti-plasmodium falciparum antibodies
AT411262B (de) * 2001-09-27 2003-11-25 Wolff Klaus Dr Humanes endogenes retrovirus
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
EP1746157A4 (fr) 2004-04-27 2009-02-18 Chugai Pharmaceutical Co Ltd Methode de proliferation de cellule plasmatique
FR2890859B1 (fr) 2005-09-21 2012-12-21 Oreal Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase
WO2008110372A1 (fr) * 2007-03-13 2008-09-18 University Of Zurich Anticorps monoclonal humain spécifique d'une tumeur
JP5797403B2 (ja) * 2007-08-03 2015-10-21 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント ヒトモノクローナル抗体およびそれを産生する方法
JPWO2009147864A1 (ja) * 2008-06-04 2011-10-27 静岡県 １細胞レベルでの抗体遺伝子の解析・同定方法
CN101885758B (zh) * 2009-05-11 2014-04-30 中国医学科学院肿瘤研究所 一种自身抗原表位、其编码基因及其用途
JP2014518889A (ja) * 2011-06-03 2014-08-07 シーティー アトランティック リミテッド Ｍａｇｅａ３結合抗体
JP2014518080A (ja) * 2011-06-27 2014-07-28 バルネバ 細胞のスクリーニング方法
EP3307876B1 (fr) 2015-06-10 2023-09-13 ImmunityBio, Inc. Cellules nk-92 modifiées pour traiter le cancer
EP3399861A4 (fr) 2016-01-07 2019-08-07 Mayo Foundation for Medical Education and Research Procédés de traitement du cancer par interféron
AU2017336094A1 (en) 2016-09-29 2019-04-18 Immunitybio, Inc. HLA class I-deficient NK-92 cells with decreased immunogenicity
WO2018129346A1 (fr) 2017-01-06 2018-07-12 Nantkwest, Inc. Cellules nk-92 génétiquement modifiées à expression réduite de cd96/tigit
US20210187024A1 (en) 2017-11-01 2021-06-24 Nantkwest, Inc. NK-92 Cells to Stimulate Anti-Cancer Vaccine
DE112019000608B4 (de) 2018-01-31 2021-05-06 Nantkwest, Inc. Verwendung von 5 % humanalbumin in wasch- und erntemedien
WO2019177986A1 (fr) 2018-03-12 2019-09-19 Nantkwest, Inc. Utilisation de cellules nk à haute affinité modifiées par cd33car (t-hank) pour réduire l'activité suppressive de cellules suppressives d'origine myéloïde (ou réduire l'impact négatif sur l'activité des cellules nk)
AU2019274392A1 (en) 2018-05-22 2020-11-05 Nantkwest, Inc. Basal media for growing NK-92 cells
KR102587512B1 (ko) 2018-05-22 2023-10-11 이뮤너티바이오, 인크. 폴록사머를 사용한 nk-92 세포 성장의 최적화
KR20240042263A (ko) 2018-05-22 2024-04-01 난트퀘스트, 인크. Fc-엡실론 car
WO2020014245A1 (fr) 2018-07-10 2020-01-16 Nantkwest, Inc. Cryoconservation
AU2019300782B2 (en) 2018-07-10 2023-12-21 Immunitybio, Inc. Generating CIK NKT cells from cord blood
CA3106324C (fr) 2018-08-01 2024-04-02 Nantkwest, Inc. Systeme quadricistronique comprenant un recepteur de homing ou une cytokine, et un recepteur d'antigene chimerique pour la modification genetique stable d'immunotherapies cellulaires
WO2020028654A1 (fr) 2018-08-01 2020-02-06 Nantkwest, Inc. Dosage combiné d'invasion et de cytotoxicité à l'aide de cellules cibles sécrétant des chimiokines
US20210324042A1 (en) 2018-08-01 2021-10-21 Nantkwest, Inc. Chemokine responsive activated natural killer cells with secondary homing activation for verified targets
KR102569842B1 (ko) 2018-11-06 2023-08-23 난트퀘스트, 인크. 키메라 항원 수용체-변형된 nk-92 세포
CN113164521A (zh) 2018-11-26 2021-07-23 免疫生物公司 具有稳定的Fc受体表达的IL-2依赖性NK-92细胞
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
WO2023081163A1 (fr) 2021-11-02 2023-05-11 Immunitybio, Inc. Cellules tueuses naturelles pour une thérapie contre les chordomes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994011507A2 (fr) * 1992-11-19 1994-05-26 Gingeras Thomas R Production d'anticorps monoclonaux recombines sans utilisation d'hybridomes et par culture in vitro de fragment de rate combinee avec la replication autonome isothermique de sequences d'arn

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0020460A1 *

Also Published As

Publication number Publication date
WO2000020460A1 (fr) 2000-04-13
AU6266899A (en) 2000-04-26

Similar Documents

Publication Publication Date Title
WO2000020460A1 (fr) Production d'anticorps specifiques d'antigenes tumoraux humains
CN109096396B (zh) 一种抗pd-l1人源化纳米抗体及其应用
CN107216389B (zh) 抗pd-l1纳米抗体及其编码序列和用途
WO2020063787A1 (fr) Anticorps monoclonal anti-b7-h3 et son utilisation en thérapie cellulaire
EP0625200B1 (fr) Proteine de liaison biosynthetique pour marqueur de cancer
JP2022548066A (ja) 抗ｐｄ－ｌ１単一ドメイン抗体ならびにその誘導体および使用
KR101570702B1 (ko) 단일클론 인간 종양-특이적 항체
CA2182369A1 (fr) Anticorps monoclonaux qui se fixent a un precurseur de l'antigene de rejet de tumeurs et qui est du type mage-1, mage-1 produit par recombinaison ou un peptide immunogene derive de mage-1
KR20040044408A (ko) 항 ｔｒａｉｌ-ｒ 항체
CN116003598B (zh) 靶向人gprc5d的重组人源化单克隆抗体及其应用
KR20080068056A (ko) 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링
MXPA06004035A (es) Aglutinantes cd3 de-inmunizados multi-especificos.
US20070149768A1 (en) Specific human antibodies for selective cancer therapy
US20230348627A1 (en) Anti-4-1bb-anti-pd-l1 bispecific antibody, and pharmaceutical composition and use thereof
WO2022057875A1 (fr) Anticorps à domaine unique ciblant 4-1bb, sa protéine de fusion, composition pharmaceutique et utilisation associées
CZ20031983A3 (cs) Specifické protilátky pro selektivní léčbu rakoviny
KR20230084155A (ko) 면역치료 조성물
US5849877A (en) Antigen-binding sites of antibody molecules specific for cancer antigens
JP2005333993A (ja) 新規なダイアボディ型二重特異性抗体
JP3231262B2 (ja) ヒトＴｈ１特異的タンパク質及びこれをコードする遺伝子、並びにこれに関連する形質転換体、組換えベクター及び抗体
US5811267A (en) Isolated nucleic acid molecules encoding antigen binding sites of antibody molecules specific for cancer antigens
CN113461825A (zh) 一种抗pd-l2纳米抗体及其应用
CN116496396B (zh) 抗cd70纳米抗体及其用途
CN111349164B (zh) 糖基磷脂酰肌醇锚定糖蛋白（c4.4a）的单克隆抗体及其应用
CN113321730B (zh) Cldn18.2抗体及其应用

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010327

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040401